Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Bristol Myers Squibb
Deal Size : $5,000.0 million
Deal Type : Collaboration
Evotec Gets Payment from BMS After IND Acceptance in Protein Degradation Partnership
Details : The collaboration aims to advance oncology research through targeting the Cereblon E3 ligase with an undisclosed miscellaneous product.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $200.0 million
November 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Bristol Myers Squibb
Deal Size : $5,000.0 million
Deal Type : Collaboration
Lead Product(s) : BMS-986419
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Evotec Advances Preclinical Neuroscience Partnership with Bristol Myers Squibb
Details : The collaboration aims to advance BMS-986419, a small molecule product, targeting EIF2B1.
Product Name : BMS-986419
Product Type : Miscellaneous
Upfront Cash : $50.0 million
October 27, 2025
Lead Product(s) : BMS-986419
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Peptone
Deal Size : Undisclosed
Deal Type : Partnership
Peptone Partners with Evotec to Target IDPs and Scale Small-Molecule Therapies
Details : Through the partnership, Peptone will harness Evotec's drug discovery toolbox, encompassing deep domain expertise in oncology and immunology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Peptone
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Korea Institute of Advanced Technology
Deal Size : $4.5 million
Deal Type : Funding
Evotec Receives Grant to Develop Novel Antibody Treatments for Lung Diseases
Details : The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Korea Institute of Advanced Technology
Deal Size : $4.5 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : X-Chem
Deal Size : Undisclosed
Deal Type : Collaboration
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Details : The collaboration aims to accelerate early-stage drug discovery by using X-Chem’s DEL technology which streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : X-Chem
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : EVT8683
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Details : A target-based programme progresses into late preclinical development, contributing to pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $50.0 million
August 08, 2024
Lead Product(s) : EVT8683
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Details : Evotec will collaborate with Pfizer to discover, and research potential new first-in-class therapeutic approaches for the treatment of metabolic and infectious diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Details : A target-based programme progresses into late preclinical development, contributing to pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
June 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $4,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Inserm
Deal Size : Undisclosed
Deal Type : Collaboration
Evotec, Inserm, Lille University Hospital Collaborate on Therapeutic Targets in Obesity
Details : The collaboration aims to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases by leveraging PanOmics technologies of Evotech.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Inserm
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Collaboration
Bayer and Evotec Collaborate to Advance Precision Cardiology
Details : The collaboration aims to identify & validate novel targets building a portfolio of precision cardiology therapeutics by leveraging Evotec's disease modeling with human induced pluripotent stem cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
